State of the Art: Treatment Update in Prostate Cancer- Oliver Sartor
November 2, 2018
Oliver Sartor and Charles Ryan discuss radioligand therapy, differentiating radioisotopes by properties and clinical application. They move to review the PSMA targeted agents and the clinical use of these agents in the treatment of prostate cancer.
Biographies:
A. Oliver Sartor, MD, Professor of Medicine, Medical Director, Tulane Cancer Center; C. E. and Bernadine Laborde Professor of Cancer Research, Tulane University
Charles J. Ryan, MD
Biographies:
A. Oliver Sartor, MD, Professor of Medicine, Medical Director, Tulane Cancer Center; C. E. and Bernadine Laborde Professor of Cancer Research, Tulane University
Charles J. Ryan, MD
Related Content:
Clinical Experience of 100 Consecutive Patients Treated with Lu-177-labeled PSMA-I&T Radioligand Therapy for mCRPC
Non-Metastatic Castration Resistant Prostate Cancer
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Clinical Experience of 100 Consecutive Patients Treated with Lu-177-labeled PSMA-I&T Radioligand Therapy for mCRPC
Non-Metastatic Castration Resistant Prostate Cancer
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)